What are the guideline‑recommended hormone therapy options and dosing for a healthy postmenopausal woman without a history of breast cancer, estrogen‑dependent tumor, or active liver disease, including recommendations for women with an intact uterus versus those who have had a hysterectomy?

Hormone Therapy for Menopause: Evidence-Based Recommendations

For healthy postmenopausal women without contraindications, initiate estrogen-only therapy (ET) for those who have had a hysterectomy, and estrogen plus progestogen therapy (EPT) for those with an intact uterus, using FDA-approved preparations at the lowest effective dose. 1

Core Treatment Algorithm by Uterine Status

Women WITHOUT a Uterus (Post-Hysterectomy)

• Prescribe estrogen-only therapy (ET) 1
• No progestogen needed (no endometrial protection required)
• Estrogen-alone therapy does not increase breast cancer incidence and is associated with reduced mortality 2

Women WITH an Intact Uterus

• Prescribe estrogen plus progestogen therapy (EPT) 1
• Progestogen is mandatory for endometrial protection
• Preferred options:
  • Transdermal estradiol + micronized progesterone (first-line for moderate CVD risk) 1
  • Conjugated equine estrogens (CEE) + bazedoxifene (BZA) where available 1
• Micronized progesterone demonstrates a more favorable breast safety profile than synthetic progestins 2, 3

Cardiovascular Risk Stratification (Critical Decision Point)

Age and timing matter significantly for safety:

Low CVD Risk (Age <60 or <10 years post-menopause)

• MHT is appropriate for bothersome vasomotor symptoms 1
• Benefits outweigh risks in this window 4, 3
• Potential cardiovascular and cognitive benefits when initiated early 3

Moderate CVD Risk

• Use transdermal estradiol as first-line (alone or with micronized progesterone) 1
• Transdermal route has lower thrombotic risk than oral 5, 3

High CVD Risk

• Recommend nonhormonal therapies instead of MHT 1
• SSRIs/SNRIs or neurokinin-3 receptor antagonists 1, 2

Critical Contraindications (Do Not Prescribe MHT)

• History of breast cancer or estrogen-dependent tumor (per question parameters)
• Active liver disease (per question parameters)
• Current cardiovascular disease 4
• History of stroke or TIA 6
• Active thromboembolic disorders 4
• Current endometrial cancer

Formulation and Dosing Principles

Use only FDA-approved preparations; avoid custom-compounded hormones 1

Route Selection

• Transdermal estradiol preferred for women with moderate CVD risk or VTE concerns 1, 3
• Lower risk of venous thromboembolism compared to oral 3
• Oral formulations remain appropriate for low-risk women 7

Dose Strategy

• Start with the lowest effective dose 4, 3
• Risks increase with higher doses and longer duration 4
• Tailor to individual symptom control and risk profile 1

Alternative Options

For Women with Intact Uterus

• CEE/bazedoxifene combination provides VMS relief and bone protection without increasing mammographic density 1, 2
• Long-term oncologic outcomes still unknown 2

Tibolone (Where Available)

• Alternative to standard MHT for VMS and climacteric symptoms 1
• Do NOT use in women with breast cancer history 1
• Do NOT combine with other MHT 1

Genitourinary Symptoms Only

• Low-dose vaginal estrogen is preferred for isolated genitourinary syndrome of menopause 4, 3
• Systemic absorption minimal
• Safe even in most breast cancer survivors 2, 3

Monitoring and Duration

Annual Reassessment Required

• Revisit the decision to continue MHT at least annually 1
• Target shortest duration consistent with treatment goals 1
• Risks increase with duration, particularly breast cancer with EPT 1, 4

Breast Cancer Surveillance

• Inform patients about increased breast cancer risk during and after EPT 1
• Emphasize adherence to age-appropriate screening 1
• Combined EPT carries small, duration-dependent increase in breast cancer risk 2

Unscheduled Bleeding

• Evaluate immediately to rule out endometrial hyperplasia and cancer 1

Common Pitfalls to Avoid

1. Do not use MHT for chronic disease prevention in women >60 years or >10 years post-menopause 8

   • USPSTF recommends against this indication (Grade D) 8
   • Increased risks of stroke, dementia, and breast cancer outweigh benefits 8

2. Do not prescribe custom-compounded bioidentical hormones 1

   • Lack FDA oversight and standardization
   • No evidence of superior safety or efficacy

3. Do not combine tibolone with other MHT forms 1

4. Do not omit progestogen in women with intact uterus

   • Unopposed estrogen increases endometrial cancer risk

Shared Decision-Making Framework

Engage in shared decision-making for: 1

• Choice of formulation (oral vs. transdermal)
• Starting dose
• Route of administration
• Discontinuation strategy (gradual taper vs. abrupt cessation) 1

This approach balances symptom relief with safety, prioritizing quality of life while minimizing cardiovascular, thrombotic, and oncologic risks through appropriate patient selection, formulation choice, and ongoing monitoring.